Login / Signup

BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020.

Haitham HamodaSusan R DavisAntonio CanoEdward MorrisSonia DavisonNicholas PanayMary A LumsdenT C HillardTommaso Simoncini
Published in: Post reproductive health (2021)
Keyphrases
  • breast cancer risk
  • risk assessment
  • human health
  • adverse drug
  • heavy metals
  • clinical practice
  • stem cells
  • climate change